The results of the KEYNOTE-689 trial reported by Uppaluri et al. (July 3 issue)1 are highly important. The addition of perioperative pembrolizumab has become the new standard of ...

The painkilling, antipyretic, and antiinflammatory properties of aspirin have been known for centuries. The understanding that aspirin targets cyclooxygenase-1 (COX-1) (also known as ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide ...

Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

Michael Welsh, Jesús González, and Paul Negulescu have won the 2025 Lasker–DeBakey Clinical Medical Research Award for their roles in developing treatments for cystic fibrosis.

There is an urgent need for low- and middle-income countries to ensure equitable, affordable, and sustained access to tobacco-cessation medications at scale.

Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 10).